Who we are

We are a growing pharmaceutical company and a dedicated ally to healthcare providers treating patients with critical conditions.

Our portfolio of products, many of them lifesaving, is focused on emergency care and rare diseases.

Our expertise lies in mastering complex products, navigating complicated regulatory pathways, and serving niche patient populations.

Emergency Care: SERB has the broadest antidote portfolio in the world, including medical countermeasures for chemical, biological, radiological and nuclear (CBRN) risks. This makes us a trusted partner and one-stop-shop for hospitals, emergency services, health departments, and governments.

Rare Diseases: Our growing rare disease portfolio helps patients with rare neurologic syndromes, metabolic disorders, and rare conditions in oncology. We work to help these patients get the diagnosis they need and access to the treatment options they deserve. This “patient first” culture has helped us to build long-term relationships with the patient groups and key opinion leaders.

80+

Medicines

400

dedicated employees

Direct sales in

18

countries

Supplying

100+

countries

An end-to-end platform

We are a fully integrated pharmaceutical company, but we remain agile.

Our goal is to optimise every stage of the pharma value chain through a perfect balance of in-house capabilities and closely managed external partners.  Our unique set of expertise allows us to determine what to do ourselves and what to outsource to trusted partners.  This allows us to efficiently acquire, develop, and manufacture our medicines to the highest standards, and reliably supply them worldwide.

  • Sales and Marketing

    Our global commercial platform is comprised of sales and marketing teams across key geographies of Europe, the Middle East, and the United States. They have deep local expertise and strong relationships with healthcare professionals, purchasing organisations, key opinion leaders, and patient associations. We also work with an extensive network of trusted distribution partners to reach a further 80 countries.

  • Delivering Innovation

    We have a pipeline of R&D and lifecycle projects focused on areas of high unmet needs. These range from developing new products to label extensions and registration in new markets. Our antibody platform offers unique opportunities to develop new antidotes and therapies, while other opportunities are explored through contract research organisations and independent investigators.

  • Business Development

    Our business development team evaluate opportunities, facilitate quick decisions, and execute complex transactions. We have a track record of integration that ensures we unlock the full growth potential of acquired products, portfolios, and businesses. These capabilities allow us to offer prospective partners attractive value propositions, and creative deal structures. Read more about Partnering with SERB.

  • Quality Manufacturing

    SERB has a hybrid approach to manufacturing. We have a best-in-class technological platform for the manufacture of polyclonal antibodies, with 4 manufacturing facilities located on three continents. Small and macro molecule manufacturing operations and logistics are outsourced to trusted European contract manufacturers with close oversight by our experienced in-house team.

  • Pharma Expertise

    Our team of industry experts provide technical support for our in-house pharma operations and carefully manage our outsourced  infrastructure. We have a unique and flexible set of capabilities in quality, regulatory, product registration, and pharmacovigilance. In addition to supporting our current portfolio, these professionals help to deliver R&D projects, perform due diligence, and integrate acquired assets.

  • A history of serving patients
    “In 2001 we were a small French company with 10 employees. Today, a team of 470 talented, committed employees are supplying more than 80 medicines around the world. Our purpose is unchanged: We want to be an essential partner to healthcare professionals. Every day we do our very best to deliver critical, life-saving medicines for patients.”

    Jeremie Urbain, Chairman

  • Purpose and values
    Our culture and ways of working are crucial to our success.
  • Leadership
    SERB’s Executive Committee is responsible for leading the group and providing appropriate governance.
  • Responsibility
    Delivering on our vision via sustainable business practices, implemented ethically and respectful of diversity.
You are leaving the SERB.com global corporate website
This link will take you to a third-party website, the terms of use and the privacy policy of which may be different. SERB declines all responsibility in that regard and in case of a breach of its privacy policy by the third-party website. Moreover, SERB is not responsible for any information or opinion contained in any third-party website.
Choose your region